C12N 2740/15071
Demonstrated in vivo effect
C12N2740/15071 (Demonstrated in vivo effect) appears on 56 US grants and 109 published applications in this corpus.
Search patents in C12N- Granted patents
- 56
- Published applications
- 109
- Assignees
- 78
- Inventors
- 213
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2005 | 0 | 1 |
| 2006 | 0 | 2 |
| 2007 | 0 | 4 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 2 |
| 2011 | 0 | 5 |
| 2012 | 0 | 1 |
| 2013 | 0 | 5 |
| 2014 | 7 | 5 |
| 2015 | 8 | 11 |
| 2016 | 10 | 17 |
| 2017 | 4 | 5 |
| 2018 | 7 | 3 |
| 2019 | 5 | 7 |
| 2020 | 3 | 5 |
| 2021 | 2 | 7 |
| 2022 | 3 | 6 |
| 2023 | 2 | 12 |
| 2024 | 0 | 7 |
| 2025 | 1 | 1 |
| 2026 | 4 | 3 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- KIR 7.1 gene therapy vectors and methods of using the same18 Aug 2026US 12,709,760 B2Wisconsin Alumni Research Foundation
- Vectors and compositions for treating hemoglobinopathies11 Aug 2026US 12,703,864 B2Children's Medical Center Corporation
- Persistent memory T-cell responses to cancer and infectious-disease antigens by manipulation of amino acid-catabolism pathways24 Mar 2026US 12,582,709 B2The Regents of the University of California
- CD33 targeted immunotherapies17 Feb 2026US 12,552,855 B2Inhibrx Biosciences, Inc.
- Method for treating muscular dystrophy by targeting LAMA1 gene23 Dec 2025US 12,502,418 B2Modalis Therapeutics Corporation
- Materials and methods for increasing immune responses within a mammal8 Oct 2026US 2026/0306668 A1Mayo Foundation for Medical Education and Research
- Compositions and methods for treating genetic disorders9 Jul 2026US 2026/0191908 A1
- Cd33 targeted immunotherapies14 May 2026US 2026/0132184 A1Inhibrx Biosciences, Inc.
- Compositions and methods for immunotherapy targeting flt3, pd-1, and/or pd-l15 Jun 2025US 2025/0179194 A1Cytoimmune Therapeutics, Inc.
- Gene therapy based administration of lentivirus vector for treating hemoglobinopathies24 Oct 2024US 2024/0350664 A1Intas Pharmaceuticals Ltd.
Most cited
By later US patents
- Methods for treatment of cancer368US 8,906,682 B2The Trustees of the University of Pennsylvania · 2014
- Compositions for treatment of cancer277US 8,911,993 B2The Trustees of the University of Pennsylvania · 2014
- Methods for treatment of cancer216US 8,916,381 B1The Trustees of the University of Pennyslvania · 2014
- Compositions for treatment of cancer199US 8,975,071 B1The Trustees of the University of Pennsylvania · 2015
- Methods for treatment of cancer199US 9,101,584 B2The Trustees of the University of Pennsylvania · 2015